Company intelligence / Profile preview

Pan-Biome Pharmaceuticals, Inc.

Vancouver, British Columbia, Canadapan-biomepharmaceuticals.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has reported positive results in preclinical trials for colitis. Their lead compound activates anti-inflammatory cytokine IL-10 and inhibits pro-inflammatory cytokines TNF-a, IL-1b, and IL-6. It also activates NRF2 and AMPK expression, which are important in delaying aging. The compound has shown to extend lifespan in C. elegans by 30% and modulates the gut microbiome, increasing beneficial bacteria like Akkermansia muciniphila[3][5][6].

Therapeutic areas: OtherGastroenterologyImmunology
Modalities: Small moleculesnatural product-based compounds
Industry: Biotech

Drug pipeline

2 assets

PB-007-3

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pan-Biome Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pan-Biome Pharmaceuticals, Inc..

Explore the full profile